Piramal Pharma

    PPLPHARMA
    Pharma
    ₹238.95
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹31,687 Cr

    P/E
    58.15
    Day range
    ₹237.32 – ₹243.76
    52-week range
    ₹132.30 – ₹253.90
    Volume
    28.30 L
    Open
    ₹240.70
    Prev close
    ₹240.70

    Latest results · Q2 FY27(consolidated)Revenue ₹2,617 Cr+28.1%Profit ₹5 CrMargin 0.2%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 48 / 100

    Factor percentiles

    Value47
    Quality14
    Momentum82
    Low volatility47

    Derived metrics

    Earn. yield
    1.7%
    ROE ÷ P/B
    -1.0%
    12-1 mom.
    +1.2%
    Return / vol
    0.62
    Magic Formula
    #589
    Piotroski
    0/6
    FCF yield
    2.4%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Piramal PharmaPPLPHARMA₹31,687 Cr58.154.00-4.0%3.0%13.3%0.72+28.1%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1m ago

    Headlines about Piramal Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    Price / Book
    3.90
    ROE (FY26)
    -4.0%
    ROCE (latest year)
    3%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹228.44
    Price above
    50-day
    ₹214.58
    Price above
    200-day
    ₹181.7
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +7.8%
    Revenue YoY (Sep 2026)
    +28.1%
    Operating margin
    13.3%
    Net margin
    0.2%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -1K Cr0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Public
    • Promoter
    • DII
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-5K Cr-2.5K Cr0 Cr2.5K Cr5K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY22FY23FY24FY25FY26-5%0%5%10%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,958.572,552.361,951.142,241.752,204.222,754.071,933.712,043.722,139.872,751.772,269.922,617.06
    YoY Sales growth——————-0.89-8.83-2.92-0.08——
    Expenses1,690.202,022.431,746.651,900.141,866.482,193.081,827.011,885.031,944.142,291.262,074.722,268.32
    Operating Profit268.37529.93204.49341.61337.74560.99106.70158.69195.73460.51195.20348.74
    OPM %13.7%20.8%10.5%15.2%15.3%20.4%5.5%7.8%9.2%16.7%8.6%13.3%
    Other Income43.197.9041.9478.3729.1858.2597.7180.3912.39-116.14108.9753.67
    Interest105.88114.22106.96107.64103.31103.6886.1582.4289.2482.9988.0887.63
    Depreciation186.32196.13184.55192.22196.81242.76197.28202.84212.74218.38223.55233.15
    Profit before tax19.36227.48-45.08120.1266.80272.80-79.02-46.18-93.8643-7.4681.63
    Tax %47.8%55.5%96.6%81.2%94.5%43.7%3.4%114.8%45.1%120.5%830.2%93.8%
    Net Profit10.11101.27-88.6422.593.68153.50-81.70-99.22-136.19-8.83-69.395.03
    EPS in Rs₹0.08₹0.77₹-0.67₹0.17₹0.03₹1.16₹-0.61₹-0.75₹-1.02₹-0.07₹-0.52₹0.04

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days89

    -2 days since Mar 2021

    Inventory Days345

    +127 days since Mar 2021

    Days Payable279

    +116 days since Mar 2021

    Cash Conversion Cycle155

    +8 days since Mar 2021

    Working Capital Days44

    0 days since Mar 2021

    Strengths, risks & growth

    Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 4.00 times its book value
    • Company has low interest coverage ratio.
    • The company has delivered a poor sales growth of 7.03% over past five years.
    • Company has a low return on equity of -0.88% over last 3 years.
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +7%
    3 Years
    +8%
    TTM
    +9%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    —
    3 Years
    -31%
    TTM
    -81%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +28%
    1 Year
    +25%

    Return on Equity

    10 Years
    —
    5 Years
    0%
    3 Years
    -1%
    Last Year
    -4%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter34.85%34.85%34.80%34.80%0.00 pp
    FII29.66%30.17%12.51%13.65%+1.14 pp
    DII15.68%15.61%14.57%14.43%-0.14 pp
    Public19.35%19.01%37.62%36.72%-0.90 pp
    Others0.44%0.34%0.48%0.40%-0.08 pp

    Filed with NSE for Sept 2026: promoters 34.80%, public 64.80%

    Analysts & fund holdings

    100%
    100% recommend buy
    11 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E58.1 vs 45.1
    Sector P/B6.03
    Beta1.19

    Who holds the shares, quarter by quarter

    Mutual funds 12.76% (-0.48 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters34.9%
    • Foreign institutions13.7%
    • Mutual funds12.8%
    • Insurance1.2%
    • Other domestic institutions0.5%
    • Retail9.7%
    • Others27.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund4.89%1.41%+0.03 pp
    Nippon India Pharma Fund0.75%2.61%+0.52 pp
    Bandhan Small Cap Fund0.73%0.67%+0.04 pp
    Axis Small Cap Fund0.47%0.51%+0.51 pp
    Franklin India Opportunities Fund0.46%1.60%+0.31 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    Avg
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    36.0%
    Downside volatility
    31.2%
    Worst 5% of days
    3.8%
    Average of that tail
    4.4%
    Max drawdown (1Y)
    36.0%
    Below its peak
    3.0%

    Against the market

    Beta vs Nifty 50
    1.03
    Correlation
    0.39
    Relative strength (3M)
    +12.8%
    ATR (14)
    3.8%

    Return

    Return 1M
    +20.8%
    Return 3M
    +16.7%
    Return 6M
    +36.5%
    Return 1Y
    +22.3%
    vs 200-day average
    +31.5%

    Momentum

    RSI (14)
    62.9
    MACD histogram
    0.29
    Stochastic %K
    47.1
    ADX (14)
    39.7
    +DI / −DI
    26.2 / 10.4
    Money flow index
    74.7

    Participation

    Delivery (20d avg)
    38.4%
    vs its 60-day baseline
    -2.4 pts
    Volume vs 20-day
    -0.4σ
    Close vs day's VWAP
    -0.9%
    52-week position
    93 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    0 of 6 tested

    • Return on assets positive — failed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹763 Cr
    FCF yield
    2.4%
    Cash conversion
    -5.07
    Accruals ratio
    -0.110
    Net debt
    ₹5,328 Cr
    Net debt / equity
    0.65
    EV / sales
    3.79
    Capex intensity
    10.0%
    Revenue CAGR
    -3.3%
    Profit CAGR
    -89.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.14 Per Share

      16 Jul 2025
      ex-date
    • dividend
      ₹0.11

      Dividend - Rs 0.11 Per Share

      12 Jul 2024
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 5:46 @ Premium Rs 71/-

      2 Aug 2023
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September, 2026

    Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....

    Company Update
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited

    Please refer attachment.

    Company Update
    Clarification On News Item Which Appeared In The 'Www.Thehindubusinessline.Com' Dated September 30, 2026 Captioned 'Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal Pharma'S Aurora Facility.'

    Please refer attachment.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.

    Company UpdatePrice-sensitive
    Clarification sought from Piramal Pharma Ltd

    The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....

    Insider Trading / SAST
    Closure of Trading Window

    Please refer the attachment.

    Company Update
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please refer attachment.

    Company Update
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited

    Please refer attached file

    Company Update
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - FDA Inspection

    Please refer attached file

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Please refer attached file

    Company Update
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

    Please refer attached file

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG

    Company Update
    Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26

    Please refer attached file

    Filed with BSE (scrip 543635); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Rights issue - Letter of Offer

      Piramal Pharma Limited - Letter of Offer

      28 Jul 2023
      Read on SEBI
    • Rights issue - DLOF

      Piramal Pharma Limited - DLOF

      31 Mar 2023
      Read on SEBI

    Regulatory orders

    • Order

      Order under section 15-I of SEBI Act 1992 in the matter of Piramal Pharma Limited

      8 Nov 2024
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Piramal Pharma Ltd. in the matter of Piramal Enterprises Ltd.

      31 Aug 2023
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Piramal Pharma: common questions

    Answered from the figures on this page.

    Piramal Pharma last traded at ₹238.95 (NSE, as of 18 Nov 2026). The last session moved it down 0.73%.

    Piramal Pharma is valued at about ₹31,687 crore (NSE, as of 18 Nov 2026).

    Piramal Pharma trades at a price-to-earnings ratio of 58.15 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Piramal Pharma has traded between ₹132.30 and ₹253.90 over the past 52 weeks, to 18 Nov 2026. It is currently 88% of the way up that range.

    Piramal Pharma (PPLPHARMA) is classified under Pharma on this site's screener.